A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This literature review assessed the burden of treatment-resistant depression in the United States by compiling published data about the clinical, societal, and economic outcomes associated with failure to respond to one or more adequate trials of drug therapy. METHODS: PubMed and the Tufts Cost-Effectiveness Analyses Registry were searched for English-language articles published between January 1996 and August 2013 that collected primary data about treatment-resistant depression. Two researchers independently assessed study quality and extracted data. RESULTS: Sixty-two articles were included (N=59,462 patients). Patients with treatment-resistant depression had 3.8±2.1 prior depressive episodes and illness duration of 4.4±3.3 years and had completed 4.7±2.7 unsuccessful drug trials involving 2.1±.3 drug classes. Response rates for treatment-resistant depression were 36%±1%. A total of 17%±6% of patients had prior suicide attempts (1.1±.2 attempts per patient). Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response. Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression. CONCLUSIONS: Treatment-resistant depression exacts a substantial toll on patients' quality of life. At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion. These findings underscore the need for research on the mechanisms of depression, new therapeutic targets, existing and new treatment combinations, and tests to improve the efficacy of and adherence to treatments for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As many as 30% of patients with MDD do not adequately respond to two therapies and are considered to be treatment resistant.”
In the citing paper
“Among private payers, the mean annual direct healthcare costs per patient for the management of TRD (US$13,196; 2013 GBP8437) were higher than for management of treatment-responsive depression (US$7715; 2013 GBP4933) 14”
In the citing paper
“These cardiovascular effects may complicate treatment of patients with TRD who, in real-world settings, often have hypertension (67%) and cardiovascular disease (56%) [15].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [15]
In the citing paper
“the mean quality of life is estimated to be 20% lower in TRS compared with non-TRS. 41 Mean quality of life is approximately 25-40% lower in patients with TRD compared with patients who respond to treatment or who are in remission; 46”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [46]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Childhood and adolescent depression: a review of the past 10 years, Part I
BIRMAHER, B., RYAN, N. D., WILLIAMSON, D. E., BRENT, D. A., KAUFMAN, J., DAHL, R. E., PEREL, J., & NELSON, B. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00011 · Cited by 2,076
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Williams, D. R., González, H. M., Neighbors, H., Nesse, R., Abelson, J. M., Sweetman, J., & Jackson, J. S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.305 · Cited by 1,293
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.034 · Cited by 1,024
Research works printed but not linked: 3
- Nierenberg AA, 2001, Journal of Clinical Psychiatry, 62, 5
- Thase ME, 1997, Journal of Clinical Psychiatry, 58, 23
- 1976, Clinical Global Impression (CGI)
Cited by
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Twenge, J. M., Cooper, A. B., Joiner, T. E., Duffy, M. E., & Binau, S. G. (2019) · Journal of Abnormal Psychology · doi:10.1037/abn0000410 · Cited by 1,469
Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway
Dang, R., Wang, M., Li, X., Wang, H., Liu, L., Wu, Q., Zhao, J., Ji, P., Zhong, L., Licinio, J., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02400-6 · Cited by 520
“Although there are available antidepressants, most of the pharmacologic interventions take weeks to months to produce effects and have low response rates [3, 4].”
BackgroundZhdanava, M., Pilon, D., Ghelerter, I., Chow, W., Joshi, K., Lefebvre, P., & Sheehan, J. J. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13699 · Cited by 523
Gordon, B. R., McDowell, C. P., Hallgren, M., Meyer, J. D., Lyons, M., & Herring, M. P. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0572 · Cited by 498
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
The excess costs of depression: a systematic review and meta-analysis
König, H., König, H.-H., & Konnopka, A. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000180 · Cited by 409
“Previous systematic reviews of COI-studies of depression addressed specific subtypes or age groups or the costs of depression as comorbidity of somatic diseases (Lehnert et al ., 2011; Luppa et al ., 2012; Molosankwe et al ., 2012; Mrazek et al ., 2014; Sambamoorthi et al ., 2017).”
Younossi, Z., Park, H., Henry, L., Adeyemi, A., & Stepanova, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.039 · Cited by 400
Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.003 · Cited by 347
“…long-term prognosis (Ghio et al., 2014), adverse changes in brain function and morphology (Ghio et al., 2014), increased side-effect burden (Mrazek et al., 2014), intensification of other medical illnesses and corresponding annual medical costs (Mrazek et al., 2014), increased suicide…”
Johnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321
Chronotype, circadian rhythm, and psychiatric disorders: Recent evidence and potential mechanisms
Zou, H., Zhou, H., Yan, R., Yao, Z., & Lu, Q. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.811771 · Cited by 269
“Depressive disorders are characterized by significant and persistent depressive symptoms as the primary clinical feature, often accompanied by the rhythmical fluctuation of mood and high morbidity, heavy burden, and great social attention (Mrazek et al., 2014; Malhi and Mann, 2018).”
BackgroundDandekar, M. P., Fenoy, A. J., Carvalho, A. F., Soares, J. C., & Quevedo, J. (2018) · Molecular Psychiatry · doi:10.1038/mp.2018.2 · Cited by 266
Jaffe, D. H., Rive, B., & Denee, T. R. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2222-4 · Cited by 237
“A systematic review conducted by Mrazek and colleagues [19] demonstrated the negative impact of TRD on health-related quality of life (HRQoL), with self-ratings between 0.”
BackgroundMethodResultInfluentialPharmacological approaches to the challenge of treatment-resistant depression
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/dionescu · Cited by 212
Vagal nerve stimulation for treatment-resistant depression
Carreno, F. R., & Frazer, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0537-8 · Cited by 208
Praharso, N. F., Tear, M. J., & Cruwys, T. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2016.11.039 · Cited by 192
“Major depression is one of the leading causes of disability worldwide (Ferrari et al., 2013) and poses a significant economic burden (Mrazek et al., 2014).”
BackgroundPham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Zhang, Y., Du, L., Bai, Y., Han, B., He, C., Gong, L., Huang, R., Shen, L., Chao, J., Liu, P., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0285-0 · Cited by 184
Glutamate and GABA Homeostasis and Neurometabolism in Major Depressive Disorder
Sarawagi, A., Soni, N. D., & Patel, A. B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.637863 · Cited by 165
Huang, R., Zhang, Y., Bai, Y., Han, B., Ju, M., Chen, B., Yang, L., Wang, Y., Zhang, H., Zhang, H., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.018 · Cited by 159
“In addition, effective antidepressant drugs are lacking and almost one-third of MDD patients do not respond adequately to current drugs (10,11).”
BackgroundRoss, E. L., Zivin, K., & Maixner, D. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0768 · Cited by 150
Li, Y.-F. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107494 · Cited by 170
Closing the Loop on Deep Brain Stimulation for Treatment-Resistant Depression
Widge, A. S., Malone, D. A., & Dougherty, D. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00175 · Cited by 143
“TRD patients rate their quality of life about 12% worse than treatmentresponsive MDD patients (Mrazek et al., 2014).”
BackgroundRhee, T. G., Shim, S. R., Forester, B. P., Nierenberg, A. A., McIntyre, R. S., Papakostas, G. I., Krystal, J. H., Sanacora, G., & Wilkinson, S. T. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.3352 · Cited by 141
Winner, J. G., Carhart, J. M., Altar, C. A., Goldfarb, S., Allen, J. D., Lavezzari, G., Parsons, K. K., Marshak, A. G., Garavaglia, S. B., & DeChairo, B. M. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1063483 · Cited by 146
Self-citationO’Neil, A., Jacka, F. N., Quirk, S. E., Cocker, F., Taylor, C. B., Oldenburg, B., & Berk, M. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0394-0 · Cited by 135
“A recent report suggests the annual cost of depression is $200 billion in the United States alone [7], which is compounded by the impact of anxiety disorders that often co-occur.”
BackgroundTowards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
Papakostas, G. I., & Ionescu, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.92 · Cited by 129
Depression: Biological markers and treatment
Nedic Erjavec, G., Sagud, M., Nikolac Perkovic, M., Svob Strac, D., Konjevod, M., Tudor, L., Uzun, S., & Pivac, N. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110139 · Cited by 119
Domany, Y., Bleich-Cohen, M., Tarrasch, R., Meidan, R., Litvak-Lazar, O., Stoppleman, N., Schreiber, S., Bloch, M., Hendler, T., & Sharon, H. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.196 · Cited by 114
Altar, C. A., Carhart, J. M., Allen, J. D., Hall‐Flavin, D. K., DeChairo, B. M., & Winner, J. G. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.85 · Cited by 122
Self-citationCusin, C., Ionescu, D. F., Pavone, K. J., Akeju, O., Cassano, P., Taylor, N., Eikermann, M., Durham, K., Swee, M. B., Chang, T., et al. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416631828 · Cited by 111
“Unfortunately, treatment-resistant depression (TRD) accounts for 12–20% of all depressed patients, costing society US$29–US$48 billion annually (Mrazek et al., 2014; Rush et al., 2009).”
BackgroundAdministration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 110
“TRD is associated with higher risk of suicide, high relapse rates and large socioeconomic burden for patients themselves as well as for health care providers (Schosser et al. 2012; Mrazek et al. 2014; Kautzky et al. 2015).”
BackgroundSackeim, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., Demitrack, M. A., George, M. S., Prudic, J., Thase, M. E., & Rush, A. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.021 · Cited by 109
“T 2018; Olfson et al., 2018; Russell et al., 2004), and markedly reduced quality of life (Johnston et al., 2018; Mrazek et al., 2014).”
BackgroundSomani, A., & Kar, S. K. (2019) · General Psychiatry · doi:10.1136/gpsych-2019-100074 · Cited by 126
Classics in Chemical Neuroscience: Ketamine
Tyler, M. W., Yourish, H. B., Ionescu, D. F., & Haggarty, S. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00074 · Cited by 106
Davidson, B., Hamani, C., Rabin, J. S., Goubran, M., Meng, Y., Huang, Y., Baskaran, A., Sharma, S., Ozzoude, M., Richter, M. A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0737-1 · Cited by 126
Lener, M. S., & Iosifescu, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12759 · Cited by 97
Inflammation in cancer and depression: a starring role for the kynurenine pathway
Sforzini, L., Nettis, M. A., Mondelli, V., & Pariante, C. M. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05200-8 · Cited by 96
Ceramides and depression: A systematic review
Dinoff, A., Herrmann, N., & Lanctôt, K. L. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.008 · Cited by 104
Karakula-Juchnowicz, H., Rog, J., Juchnowicz, D., Łoniewski, I., Skonieczna-Żydecka, K., Krukow, P., Futyma-Jedrzejewska, M., & Kaczmarczyk, M. (2019) · Nutrition Journal · doi:10.1186/s12937-019-0475-x · Cited by 93
Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature
Ionescu, D. F., Felicione, J. M., Gosai, A., Cusin, C., Shin, P., Shapero, B. G., & Deckersbach, T. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000179 · Cited by 91
“The original neuroimaging studies on ketamine’s mechanism were thus used as working models for schizophrenia because excess glutamate has been linked to the development of schizophrenia and psychosis.7 With regard to MDD patients, decreased glutamate has been noted in various prefrontal regions, including the dorsolat…”
InfluentialMcGovern, A. S., Hamlin, A. S., & Winter, G. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419877954 · Cited by 89
“As treatment-resistant MDD presents a substantive societal burden (Mrazek et al., 2014), a better understanding of the factors that may interact with SSRI mediation of antidepressant effect is imperative.”
BackgroundJha, M., & Trivedi, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010233 · Cited by 86
“Additionally, TRD patients report higher rates of suicidality and lower quality of life as compared to treatment responsive depressed patients [27].”
BackgroundRole of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Kim, Y.-K., & Na, K.-S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.009 · Cited by 84
Culpepper, L., Muskin, P. R., & Stahl, S. M. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.07.001 · Cited by 77
“A literature review that assessed the burden of treatment-resistant depression in the United States concluded that up to 20% of patients with depression are treatment resistant and that annual added societal costs related to treatment-resistant depression are in the range of $29 to $48 billion.(16) Patients who respon…”
BackgroundPharmacogenetics in Psychiatry: An Update on Clinical Usability
van Schaik, R. H. N., Müller, D. J., Serretti, A., & Ingelman‐Sundberg, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.575540 · Cited by 86
Kondo, D. G., Forrest, L. N., Shi, X., Sung, Y.-H., Hellem, T. L., Huber, R. S., & Renshaw, P. F. (2016) · Amino Acids · doi:10.1007/s00726-016-2194-3 · Cited by 79
van der Wal, J. M., Bergfeld, I. O., Lok, A., Mantione, M., Figee, M., Notten, P., Beute, G., Horst, F., van den Munckhof, P., Schuurman, P. R., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321758 · Cited by 79
Altar, C. A., Carhart, J., Allen, J. D., Hall-Flavin, D., Winner, J., & Dechairo, B. (2015) · Complex Psychiatry · doi:10.1159/000430915 · Cited by 79
Self-citationHolz, A., Mülsch, F., Schwarz, M. K., Hollmann, M., Döbrössy, M. D., Coenen, V. A., Bartos, M., Normann, C., Biber, K., van Calker, D., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.07.011 · Cited by 79
Blomstedt, P., Naesström, M., & Bodlund, O. (2017) · Clinical Case Reports · doi:10.1002/ccr3.856 · Cited by 77
“The frequence of therapy-resistant MDD is estimated to range from 12% to 30% [12, 13].”
BackgroundExperimental medication treatment approaches for depression
Ionescu, D., & Papakostas, G. I. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.33 · Cited by 83
Zhukovsky, P., Anderson, J. A. E., Coughlan, G., Mulsant, B. H., Cipriani, A., & Voineskos, A. N. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21010088 · Cited by 87
Propofol for Treatment-Resistant Depression: A Pilot Study
Mickey, B. J., White, A. T., Arp, A. M., Leonardi, K., Torres, M. M., Larson, A. L., Odell, D. H., Whittingham, S. A., Beck, M. M., Jessop, J. E., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy085 · Cited by 73
Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
Salahudeen, M. S., Wright, C. M., & Peterson, G. M. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620937899 · Cited by 72
Do, H. T. T., & Cho, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176211 · Cited by 79
Amiri, S., Amini-Khoei, H., Mohammadi‐Asl, A., Alijanpour, S., Haj‐Mirzaian, A., Rahimi-Balaei, M., Razmi, A., Olson, C. O., Rastegar, M., Mehdizadeh, M., et al. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.04.052 · Cited by 78
Fanelli, G., Benedetti, F., Kasper, S., Zohar, J., Souery, D., Montgomery, S., Albani, D., Forloni, G., Ferentinos, P. P., Rujescu, D., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110170 · Cited by 76
Therapeutic applications of BCI technologies
McFarland, D. J., Daly, J. J., Boulay, C., & Parvaz, M. A. (2017) · Brain-Computer Interfaces · doi:10.1080/2326263x.2017.1307625 · Cited by 83
“Treatments, although available for many psychiatric conditions, remain limited in their effectiveness and efficacy and a significant number of patients remain treatment resistant [69-70], or suffer from serious side effects [71-72].”
BackgroundDoherty, T., Wajs, E., Melkote, R., Miller, J., Singh, J. B., & Weber, M. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00699-4 · Cited by 68
Primorac, D., Bach‐Rojecky, L., Vađunec, D., Juginović, A., Žunić, K., Matišić, V., Skelin, A., Arsov, B., Boban, L., Erceg, D., et al. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0134 · Cited by 90
Cano-López, J. B., García‐Sancho, E., Fernández‐Castilla, B., & Salguero, J. M. (2021) · Cognitive Therapy and Research · doi:10.1007/s10608-021-10260-2 · Cited by 84
Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System
Sussman, M., O’sullivan, A. K., Shah, A., Olfson, M., & Menzin, J. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.7.823 · Cited by 65
Lisoway, A. J., Zai, C. C. H., Tiwari, A. K., & Kennedy, J. L. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2016.12.071 · Cited by 79
van Heeringen, K., Wu, G., Vervaet, M., Vanderhasselt, M., & Baeken, C. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.10.011 · Cited by 68
SMRI Biomarkers Predict Electroconvulsive Treatment Outcomes: Accuracy with Independent Data Sets
Jiang, R., Abbott, C., Jiang, T., Du, Y., Espinoza, R. T., Narr, K. L., Wade, B., Yu, Q., Song, M., Lin, D., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.165 · Cited by 66
An update on NMDA antagonists in depression
Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 70
Modulation of amygdala reactivity following rapidly acting interventions for major depression
Loureiro, J. R. A., Leaver, A., Vasavada, M., Sahib, A. K., Kubicki, A., Joshi, S., Woods, R. P., Wade, B., Congdon, E., Espinoza, R., et al. (2020) · Human Brain Mapping · doi:10.1002/hbm.24895 · Cited by 64
Brown, L. C., Lorenz, R. A., Li, J., & DeChairo, B. M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.022 · Cited by 68
Nguyen, K., & Gordon, L. G. (2015) · Value in Health · doi:10.1016/j.jval.2015.04.004 · Cited by 67
“leading cause of disability worldwide (2, 3).”
Martín‐Hernández, D., Tendilla‐Beltrán, H., Madrigal, J. L. M., García‐Bueno, B., Leza, J. C., & Caso, J. R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1096-7 · Cited by 67
Heinz, A. J., Meffert, B. N., Halvorson, M. A., Blonigen, D., Timko, C., & Cronkite, R. (2018) · Depression and Anxiety · doi:10.1002/da.22782 · Cited by 61
Tanguay-Sela, M., Benrimoh, D. A., Popescu, C., Pérez, T., Rollins, C. P. E., Snook, E., Lundrigan, E., Armstrong, C., Perlman, K., Fratila, R., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114336 · Cited by 70
Wang, X., Wang, C., Zhang, Y., & An, Z. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04756-2 · Cited by 71
“Current treatment approaches result in a prolonged duration of unremitted illness, which is related to worsened long-term prognosis, adverse changes in cognitive function and brain morphology, and increased side effects [9, 10].”
BackgroundThe Beneficial Role of Photobiomodulation in Neurodegenerative Diseases
Abijo, A. Z., Lee, C.-Y., Huang, C.-Y., Ho, P., & Tsai, K. (2023) · Biomedicines · doi:10.3390/biomedicines11071828 · Cited by 72
Structural connectivity and response to ketamine therapy in major depression: A preliminary study
Vasavada, M. M., Leaver, A. M., Espinoza, R. T., Joshi, S. H., Njau, S. N., Woods, R. P., & Narr, K. L. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.018 · Cited by 59
“, 2006) while 10–30% remain unresponsive to two or more pharmacotherapies and are characterized as treatment-resistant (Mrazek et al., 2014).”
BackgroundHeerlein, K., Young, A. H., Otte, C., Frodl, T., Degraeve, G., Hagedoorn, W., Oliveira-Maia, A. J., Perez Sola, V., Rathod, S., Rosso, G., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.124 · Cited by 56
Zorumski, C. F., Nagele, P., Mennerick, S., & Conway, C. R. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00172 · Cited by 57
“These symptoms include: (1) low (sad) mood, (2) loss of interest in usual, particularly pleasurable activities, (3) change in appetite and body weight, (4) sleep disturbance, (5) dampened energy levels (fatigue), (6) increased (agitation) or decreased (retardation) motor activity, (7) feelings of excessive guilt and/o…”
BackgroundChen, L., Klooster, D., Tik, M., Thomas, E. H. X., Downar, J. H., Fitzgerald, P. B., Williams, N., & Baeken, C. (2023) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000364 · Cited by 67
Chung, B., Ong, M., Ettner, S. L., Jones, F., Gilmore, J., McCreary, M., Sherbourne, C., Ngo, V., Koegel, P., Tang, L., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-3011 · Cited by 56
“Shortterm change in avoiding poor quality of life and behavioral health hospitalizations, and possibly longer term, are clinically important owing to consistent mental health disparities (3–5), depression-related costs (66, 67), and the recurrent chronicity of depression (68, 69).”
Dandekar, M. P., Saxena, A., Scaini, G., Shin, J. H., Migut, A., Giridharan, V. V., Zhou, Y., Barichello, T., Soares, J. C., Quevedo, J., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1381-5 · Cited by 61
Economic impact of treatment-resistant depression: A retrospective observational study
Pérez-Sola, V., Roca, M., Alonso, J., Gabilondo, A., Hernando, T., Sicras-Mainar, A., Sicras-Navarro, A., Herrera, B., & Vieta, E. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.036 · Cited by 55
Signal Transduction Pathways of Acupuncture for Treating Some Nervous System Diseases.
Lai, H.-C., Chang, Q.-Y., & Hsieh, C.-L. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2909632 · Cited by 55
Solomon, D., Proudfoot, J., Clarke, J., & Christensen, H. (2015) · Journal of Medical Internet Research · doi:10.2196/jmir.4207 · Cited by 55
“The effects of these disorders extend beyond mental health to include diminished quality of life and functioning and increased mortality and medical morbidity for individuals [3], and substantial economic loss for society [4,5].”
Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan
Fife, D., Feng, Y., Wang, M. Y.-H., Chang, C.-J., Liu, C.-Y., Juang, H.-T., Furnback, W., Singh, J., & Wang, B. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.03.006 · Cited by 55
Mohammed, H. S. (2016) · Lasers in Medical Science · doi:10.1007/s10103-016-2033-5 · Cited by 55
“Despite that antidepressant drugs provide effective treatment for depression disorder, negative side effects of pharmacological therapy [4] and drug treatment-resistant depression [5] made the search for new antidepressant interventions become mandatory.”
Mathew, S. J., Wilkinson, S. T., Altinay, M., Asghar-Ali, A., Chang, L. C., Collins, K. A., Dale, R. M., Hu, B., Krishnan, K., Kellner, C. H., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.12.009 · Cited by 54
Ketamine induces rapid antidepressant effects via the autophagy-NLRP3 inflammasome pathway
Lyu, D., Wang, F., Zhang, M., Yang, W., Huang, H., Huang, Q., Wu, C., Qian, N., Wang, M., Zhang, H., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06201-w · Cited by 62
“Each of these is major contributor to the heavy economic and social burdens of depression (Mrazek et al. 2014).”
BackgroundExamining the role of positive and negative metacognitive beliefs in depression
Huntley, C. D., & Fisher, P. (2016) · Scandinavian Journal of Psychology · doi:10.1111/sjop.12306 · Cited by 60
Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
Pilon, D., Joshi, K., Sheehan, J. J., Zichlin, M. L., Zuckerman, P. R., Lefèbvre, P., & Greenberg, P. E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223255 · Cited by 60
Haj‐Mirzaian, A., Amiri, S., Amini-Khoei, H., Rahimi-Balaei, M., Kordjazy, N., Olson, C. O., Rastegar, M., Naserzadeh, P., Marzban, H., Dehpour, A. R., et al. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.018 · Cited by 54
Ross, E. L., & Soeteman, D. I. (2020) · Psychiatric Services · doi:10.1176/appi.ps.201900625 · Cited by 51
Hashimoto, K. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.01.003 · Cited by 58
Longitudinal effects of rTMS on neuroplasticity in chronic treatment-resistant depression
Dalhuisen, I., Ackermans, E., Martens, L., Mulders, P. C. R., Bartholomeus, J., de Bruijn, A., Spijker, J., van Eijndhoven, P., & Tendolkar, I. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01135-w · Cited by 59
Rodent models of treatment-resistant depression
Caldarone, B. J., Zachariou, V., & King, S. L. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.063 · Cited by 50
“Treatment-resistant depression has been estimated to present an annual added societal cost $29–$48 billion, making the total societal costs of major depression in the United States $106–$118 billion per year (Mrazek et al., 2014).”
BackgroundLenze, E. J., Farber, N. B., Kharasch, E., Schweiger, J., Yingling, M., Olney, J., & Newcomer, J. W. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2016.1142607 · Cited by 50
“Approximately 15–30% of individuals with depression have a severe form that is resistant to standard antidepressant treatments (Trevino et al. 2014), leading to extended suffering, excess health care costs, and elevated risk of suicide (Petersen et al. 2004; Mrazek et al. 2014).”
Ross, E. L., Vijan, S., Miller, E. M., Valenstein, M., & Zivin, K. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1480 · Cited by 50
“These values were derived from a prospective study of patients treated for MDD (39) and are consistent with utility estimates from clinical trials (52, 53).”
Fabbri, C., Kasper, S., Kautzky, A., Zohar, J., Souery, D., Montgomery, S., Albani, D., Forloni, G., Ferentinos, P. P., Rujescu, D., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0738-5 · Cited by 51
Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression
Vasavada, M. M., Loureiro, J., Kubicki, A., Sahib, A., Wade, B., Hellemann, G., Espinoza, R. T., Congdon, E., Narr, K. L., & Leaver, A. M. (2021) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.06.015 · Cited by 51
Metadata
- Authors
- Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I.
- Affiliations
- Mayo Clinic (US)
- Venue
- Psychiatric Services
- Published
- 2014-08
- Volume
- 65
- Issue
- 8
- Pages
- 977-987
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2111118992
- Cited by
- 580
- References
- 80
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 37 · 2023: 76 · 2022: 62 · 2021: 78 · 2020: 64 · 2019: 66 · 2018: 49 · 2017: 28 · 2016: 23 · 2015: 19 · 2014: 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, economic burden, social burden, quality of life, health care costs, productivity loss, treatment response rate, suicide attempts, disease duration, major depressive disorder
- MeSH terms
- Major Depressive Disorder, Depressive Disorder, Major, Humans, Quality of Life, Cost of Illness, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.